vs
ARTIVION, INC.（AORT）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
LiveRamp Holdings, Inc.的季度营收约是ARTIVION, INC.的1.8倍（$212.2M vs $116.0M），LiveRamp Holdings, Inc.净利率更高（18.8% vs 2.1%，领先16.7%），ARTIVION, INC.同比增速更快（19.2% vs 8.6%），过去两年LiveRamp Holdings, Inc.的营收复合增速更高（11.1% vs 9.1%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
AORT vs RAMP — 直观对比
营收规模更大
RAMP
是对方的1.8倍
$116.0M
营收增速更快
AORT
高出10.6%
8.6%
净利率更高
RAMP
高出16.7%
2.1%
两年增速更快
RAMP
近两年复合增速
9.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $212.2M |
| 净利润 | $2.4M | $39.9M |
| 毛利率 | 63.1% | 71.9% |
| 营业利润率 | 9.2% | 18.6% |
| 净利率 | 2.1% | 18.8% |
| 营收同比 | 19.2% | 8.6% |
| 净利润同比 | 114.7% | 255.7% |
| 每股收益（稀释后） | $0.06 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTRAMP
| Q4 25 | $116.0M | $212.2M | ||
| Q3 25 | $113.4M | $199.8M | ||
| Q2 25 | $113.0M | $194.8M | ||
| Q1 25 | $99.0M | $188.7M | ||
| Q4 24 | $97.3M | $195.4M | ||
| Q3 24 | $95.8M | $185.5M | ||
| Q2 24 | $98.0M | $176.0M | ||
| Q1 24 | $97.4M | $171.9M |
净利润AORTRAMP
| Q4 25 | $2.4M | $39.9M | ||
| Q3 25 | $6.5M | $27.4M | ||
| Q2 25 | $1.3M | $7.7M | ||
| Q1 25 | $-505.0K | $-6.3M | ||
| Q4 24 | $-16.5M | $11.2M | ||
| Q3 24 | $-2.3M | $1.7M | ||
| Q2 24 | $-2.1M | $-7.5M | ||
| Q1 24 | $7.5M | $-5.4M |
毛利率AORTRAMP
| Q4 25 | 63.1% | 71.9% | ||
| Q3 25 | 65.6% | 70.2% | ||
| Q2 25 | 64.7% | 70.1% | ||
| Q1 25 | 64.2% | 69.3% | ||
| Q4 24 | 63.2% | 71.9% | ||
| Q3 24 | 63.7% | 72.4% | ||
| Q2 24 | 64.6% | 70.6% | ||
| Q1 24 | 64.6% | 72.2% |
营业利润率AORTRAMP
| Q4 25 | 9.2% | 18.6% | ||
| Q3 25 | 11.1% | 10.7% | ||
| Q2 25 | 7.4% | 3.7% | ||
| Q1 25 | 2.2% | -6.1% | ||
| Q4 24 | 2.7% | 7.5% | ||
| Q3 24 | 4.6% | 4.0% | ||
| Q2 24 | 6.6% | -3.0% | ||
| Q1 24 | 26.0% | -8.3% |
净利率AORTRAMP
| Q4 25 | 2.1% | 18.8% | ||
| Q3 25 | 5.7% | 13.7% | ||
| Q2 25 | 1.2% | 4.0% | ||
| Q1 25 | -0.5% | -3.3% | ||
| Q4 24 | -16.9% | 5.7% | ||
| Q3 24 | -2.4% | 0.9% | ||
| Q2 24 | -2.2% | -4.3% | ||
| Q1 24 | 7.7% | -3.1% |
每股收益（稀释后）AORTRAMP
| Q4 25 | $0.06 | $0.62 | ||
| Q3 25 | $0.13 | $0.42 | ||
| Q2 25 | $0.03 | $0.12 | ||
| Q1 25 | $-0.01 | $-0.10 | ||
| Q4 24 | $-0.40 | $0.17 | ||
| Q3 24 | $-0.05 | $0.03 | ||
| Q2 24 | $-0.05 | $-0.11 | ||
| Q1 24 | $0.18 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $403.4M |
| 总债务越低越好 | $215.1M | — |
| 股东权益账面价值 | $448.2M | $962.3M |
| 总资产 | $884.8M | $1.3B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AORTRAMP
| Q4 25 | $64.9M | $403.4M | ||
| Q3 25 | $73.4M | $376.9M | ||
| Q2 25 | $53.5M | $371.1M | ||
| Q1 25 | $37.7M | $420.8M | ||
| Q4 24 | $53.5M | $384.3M | ||
| Q3 24 | $56.2M | $348.4M | ||
| Q2 24 | $55.0M | $342.7M | ||
| Q1 24 | $51.1M | $368.9M |
总债务AORTRAMP
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTRAMP
| Q4 25 | $448.2M | $962.3M | ||
| Q3 25 | $438.7M | $943.8M | ||
| Q2 25 | $419.9M | $947.8M | ||
| Q1 25 | $294.3M | $948.9M | ||
| Q4 24 | $276.2M | $957.7M | ||
| Q3 24 | $304.7M | $932.1M | ||
| Q2 24 | $295.1M | $951.9M | ||
| Q1 24 | $295.0M | $949.1M |
总资产AORTRAMP
| Q4 25 | $884.8M | $1.3B | ||
| Q3 25 | $857.7M | $1.2B | ||
| Q2 25 | $838.4M | $1.2B | ||
| Q1 25 | $791.2M | $1.3B | ||
| Q4 24 | $789.1M | $1.3B | ||
| Q3 24 | $803.1M | $1.2B | ||
| Q2 24 | $789.5M | $1.2B | ||
| Q1 24 | $784.0M | $1.2B |
负债/权益比AORTRAMP
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | — |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | — |
| 自由现金流率自由现金流/营收 | -6.9% | — |
| 资本支出强度资本支出/营收 | 23.7% | 0.1% |
| 现金转化率经营现金流/净利润 | 8.06× | — |
| 过去12个月自由现金流最近4个季度 | $839.0K | — |
8季度趋势，按日历期对齐
经营现金流AORTRAMP
| Q4 25 | $19.6M | — | ||
| Q3 25 | $22.3M | $57.4M | ||
| Q2 25 | $15.0M | $-15.8M | ||
| Q1 25 | $-17.0M | — | ||
| Q4 24 | $10.1M | $45.1M | ||
| Q3 24 | $11.5M | $55.6M | ||
| Q2 24 | $6.1M | $-9.3M | ||
| Q1 24 | $-5.5M | — |
自由现金流AORTRAMP
| Q4 25 | $-7.9M | — | ||
| Q3 25 | $17.7M | $56.8M | ||
| Q2 25 | $11.7M | $-16.2M | ||
| Q1 25 | $-20.6M | — | ||
| Q4 24 | $8.7M | $44.8M | ||
| Q3 24 | $7.8M | $55.4M | ||
| Q2 24 | $3.6M | $-9.6M | ||
| Q1 24 | $-9.1M | — |
自由现金流率AORTRAMP
| Q4 25 | -6.9% | — | ||
| Q3 25 | 15.6% | 28.4% | ||
| Q2 25 | 10.4% | -8.3% | ||
| Q1 25 | -20.8% | — | ||
| Q4 24 | 9.0% | 22.9% | ||
| Q3 24 | 8.2% | 29.8% | ||
| Q2 24 | 3.7% | -5.4% | ||
| Q1 24 | -9.3% | — |
资本支出强度AORTRAMP
| Q4 25 | 23.7% | 0.1% | ||
| Q3 25 | 4.1% | 0.3% | ||
| Q2 25 | 2.9% | 0.2% | ||
| Q1 25 | 3.7% | 0.2% | ||
| Q4 24 | 1.5% | 0.1% | ||
| Q3 24 | 3.8% | 0.1% | ||
| Q2 24 | 2.6% | 0.1% | ||
| Q1 24 | 3.7% | 1.0% |
现金转化率AORTRAMP
| Q4 25 | 8.06× | — | ||
| Q3 25 | 3.42× | 2.09× | ||
| Q2 25 | 11.16× | -2.04× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | — | 32.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.73× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
RAMP
暂无分部数据
